Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

NCT00016107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: estramustine phosphate sodium
DRUG: docetaxel
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)